Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor

Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation

“…Importantly, normal liver GluCer levels are observed in the setting of SMS2 deficiency ( Li et al., 2012 ). Thus, we and others have suggested that SMS2 could be a therapeutic target for human metabolic diseases ( Li et al., 2019 ; Mo et al., 2018 ; Sugimoto et al., 2016 ). In contrast, mice with global SMS1 deficiency exhibit moderate neonatal lethality ( Li et al., 2012 ; Yano et al., 2011 ), as more than 30% of homozygous Sms 1 global KO mice die postnatally (the remainder can grow to adulthood).…”

Serum cardiovascular-related metabolites disturbance exposed to different heavy metal exposure scenarios

“…In mouse models, activation of sphingolipid metabolism pathway caused by an elevation in sphingomyelin contributed to the inflammatory state of the liver and increased expression of CRP ( Lightle et al, 2000 ). Decreased plasma sphingomyelin levels was found to be associated with a lower secretion of pro-inflammatory cytokine in mouse ( Li et al, 2019 ). Further studies on the effect of sphingolipid are needed in order to better understand the molecular mechanism between airborne heavy metal exposures and cardiovascular-related early health effects.…”

Ceramide/Sphingomyelin Rheostat Regulated by Sphingomyelin Synthases and Chronic Diseases in Murine Models

“…Indeed, recent studies have shown the development of novel SMS2 inhibitors to suppress these inflammatory diseases in mouse model. 138 139 140 Therefore, SMS2 is strongly suggested as a potential target to develop drugs for acute phase inflammation and cancers.…”